These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 22918794)

  • 21. Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms.
    Mizuno Y; Kudo A; Akashi T; Akahoshi K; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Tanaka S; Tateishi U; Tanabe M
    J Cancer Res Clin Oncol; 2018 Jun; 144(6):1155-1163. PubMed ID: 29602973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. O6-Methylguanine DNA Methyltransferase Status Does Not Predict Response or Resistance to Alkylating Agents in Well-Differentiated Pancreatic Neuroendocrine Tumors.
    Raj N; Klimstra DS; Horvat N; Zhang L; Chou JF; Capanu M; Basturk O; Do RKG; Allen PJ; Reidy-Lagunes D
    Pancreas; 2017 Jul; 46(6):758-763. PubMed ID: 28609363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising advances in the treatment of malignant pancreatic endocrine tumors.
    Jensen RT; Delle Fave G
    N Engl J Med; 2011 Feb; 364(6):564-5. PubMed ID: 21306243
    [No Abstract]   [Full Text] [Related]  

  • 24. Advances in pancreatic neuroendocrine tumor treatment.
    Berruti A; Pia A; Terzolo M
    N Engl J Med; 2011 May; 364(19):1871-2; author reply 1873-4. PubMed ID: 21561357
    [No Abstract]   [Full Text] [Related]  

  • 25. Sunitinib in thymic carcinoma: enigmas still unresolved.
    Marx A; Weis CA
    Lancet Oncol; 2015 Feb; 16(2):124-5. PubMed ID: 25592633
    [No Abstract]   [Full Text] [Related]  

  • 26. Sunitinib in pancreatic neuroendocrine tumors.
    Raymond E; Hammel P; Dreyer C; Maatescu C; Hentic O; Ruszniewski P; Faivre S
    Target Oncol; 2012 Jun; 7(2):117-25. PubMed ID: 22661319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted agents in treatment of neuroendocrine tumors of pancreas.
    Karampelas IN; Syrigos KN; Saif MW
    JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms.
    Crippa S; Partelli S; Boninsegna L; Falconi M
    Ann Oncol; 2012 Jul; 23(7):1928. PubMed ID: 22753260
    [No Abstract]   [Full Text] [Related]  

  • 29. Circulating biomarkers of response to sunitinib in gastroenteropancreatic neuroendocrine tumors: current data and clinical outlook.
    Mateo J; Heymach JV; Zurita AJ
    Mol Diagn Ther; 2012 Jun; 16(3):151-61. PubMed ID: 22515658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
    Peng L; Schwarz RE
    Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study.
    Rinzivillo M; Fazio N; Pusceddu S; Spallanzani A; Ibrahim T; Campana D; Marconcini R; Partelli S; Badalamenti G; Brizzi MP; Catena L; Schinzari G; Carnaghi C; Berardi R; Faggiano A; Antonuzzo L; Spada F; Gritti S; Femia D; Gelsomino F; Bongiovanni A; Ricci S; Brighi N; Falconi M; Delle Fave G; Panzuto F
    Pancreatology; 2018 Mar; 18(2):198-203. PubMed ID: 29361429
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
    Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Systemic therapy for advanced pancreatic neuroendocrine tumors.
    Kulke MH
    Semin Oncol; 2013 Feb; 40(1):75-83. PubMed ID: 23391115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors.
    Kulke MH; Hornick JL; Frauenhoffer C; Hooshmand S; Ryan DP; Enzinger PC; Meyerhardt JA; Clark JW; Stuart K; Fuchs CS; Redston MS
    Clin Cancer Res; 2009 Jan; 15(1):338-45. PubMed ID: 19118063
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of the safety and efficiency of sunitinib malate in metastatic neuroendocrine tumours of the pancreas (NEN G1/G2) depending on the number and type of earlier therapeutic lines - initial report.
    Wachuła E; Ćwikła JB; Rogowski W; Boratyn-Nowicka A; Szabłowska-Siwik S; Piątek M; Zemczak A; Michalik B; Jarząb B; Nawrocki S; Kos-Kudła B
    Endokrynol Pol; 2014; 65(6):472-8. PubMed ID: 25554616
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes.
    Huda MS; Amiel SA; Ross P; Aylwin SJ
    Diabetes Care; 2014; 37(5):e87-8. PubMed ID: 24757248
    [No Abstract]   [Full Text] [Related]  

  • 37. Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial.
    Vinik A; Bottomley A; Korytowsky B; Bang YJ; Raoul JL; Valle JW; Metrakos P; Hörsch D; Mundayat R; Reisman A; Wang Z; Chao RC; Raymond E
    Target Oncol; 2016 Dec; 11(6):815-824. PubMed ID: 27924459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Locoregional and Systemic Approaches for the Treatment of Patients with Metastatic Neuroendocrine Tumors.
    Grandhi MS; Lafaro KJ; Pawlik TM
    J Gastrointest Surg; 2015 Dec; 19(12):2273-82. PubMed ID: 26341823
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib Efficacy in Patients with Advanced pNET in Clinical Practice.
    Lahner H; Rinke A; Unger N; Poeppel TD; Kühl H; Lehmann N; Führer D
    Horm Metab Res; 2016 Sep; 48(9):575-80. PubMed ID: 27101094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of sunitinib in patients with advanced neuroendocrine tumors.
    Bajetta E; Guadalupi V; Procopio G
    J Clin Oncol; 2009 Jan; 27(2):319-20; author reply 320. PubMed ID: 19064950
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.